Abstract 963P
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Early detection of HCC is critical for timely treatment and a better prognosis. In this prospective study (ASCEND-Hep, NCT04835675), we aimed to explore multi-omics including cell-free DNA (cfDNA) methylation, mutation, and α-fetoprotein (AFP) in early detection of HCC.
Methods
This multicenter study prospectively collected blood samples from patients with HCC and benign liver diseases. Age-matched non-cancer controls were obtained from a previous study. Methylation and mutation were detected through a methylation panel of 161,984 CpG sites and a cancer-associated 168-gene panel, respectively. Models were developed in a training set (cancer: 172; non-cancer: 206) and tested in a validation set (cancer: 117; non-cancer: 140). Then the locked models were validated in an independent validation set (cancer: 158; non-cancer: 637).
Results
In the training set, cfDNA methylation model had a higher area under curve than AFP and mutation alone (P<0.05). In the validation set, the methylation model yielded an overall sensitivity of 92.3% (95% CI, 85.9%–96.4%) at a specificity of 95.0% (90.0%–98.0%). Meanwhile, AFP >400 ng/mL had a sensitivity of 27.3% (18.8%–37.2%) with a specificity of 100.0% (96.5%–100.0%). Combining cfDNA methylation and AFP showed a better performance with a sensitivity of 94.0% (88.1%–97.6%) and a specificity of 95.0% (90.0%–98.0%), while the addition of mutation did not further improve the performance. Consistent results were observed in the independent validation set that the combined model achieved a sensitivity of 90.5% (84.8%–94.6%) at a specificity of 97.3% (95.8%–98.4%). The sensitivity of the combined model in Barcelona Clinic Liver Cancer Classification 0–A was 87.1% (78.0%–93.4%).
Conclusions
cfDNA methylation yielded superior performance than AFP and mutation alone. Our study highlights a potential clinical utility of combining cfDNA methylation and AFP for HCC early detection.
Clinical trial identification
NCT04835675.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Burning Rock Bioengineering Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18